Weilizhibo-B (09887): Partner OBLENIO completed the administration of LBL-051 to the first batch of patients in phase IA clinical trials in refractory autoimmune diseases

According to Zhitong Finance App, Weilizhibo-B (09887) announced that NewCo Oblenio Bio (Oblenio), which was co-founded with Aditum Bio, has completed the first batch of patients in the first phase Ia clinical trial conducted in Europe at LBL-051 (its sole asset, a three-specific T-cell connector (TCE) targeting BCMA, CD19, and CD3).

LBL-051 is designed to safely achieve complete elimination of B cells and plasma cells to achieve long-lasting immune system reset, and has the potential to bring continuous drug-free remission to patients with autoimmune diseases. Preclinical data showed that by targeting CD19 and BCMA simultaneously, LBL051 can completely eliminate B cells and plasma cells, and the level of cytokine release is extremely low.

This open-label, multicenter phase Ia study is including patients with multiple indications for refractory autoimmune diseases. The test uses subcutaneous administration to assess safety, tolerability, clinical response, clearance of B cells and plasma cells from blood and tissue, and related biomarkers. The study design has been approved by the Paul Ehrlich Institute (PEI) in Germany. Using a highly innovative dose escalation scheme for the first human trial, it is possible to quickly and carefully evaluate the effects of this treatment while prioritizing patient safety, and obtain proof-of-of-concept data for various autoimmune diseases.

This milestone fully demonstrates the company's proprietary LeadsBodyTM platform's ability to develop differentiated and globally competitive assets. Following the clinical verification of LBL-034 in the field of hematoma, LBL-051 is expected to be clinically proven again in the broad application scenarios of self-immunity, TCE technology. As the original researcher, the company will continue to provide technical support to Oblenio and will continue to be eligible for milestone payments and sales shares as LBL-051 progresses in the global clinical development and commercialization process.